Literature DB >> 12424773

Evaluating the risk of tuberous sclerosis in cases with prenatal diagnosis of cardiac rhabdomyoma.

Ronni Gamzu1, Reuven Achiron, Julius Hegesh, Ehud Weiner, Ron Tepper, Amiram Nir, Ron Rabinowitz, Ron Auslander, Simcha Yagel, Yaron Zalel, Etan Zimmer.   

Abstract

OBJECTIVE: To evaluate the prenatal parameters that increase the risk of tuberous sclerosis in prenatal management of fetal cardiac tumors suspected as rhabdomyoma.
METHODS: The study was a retrospective survey of 18 documented cases in which cardiac rhabdomyoma was suspected during pregnancy. The following parameters were evaluated as possible risk factors associated with tuberous sclerosis: tumor size, isolated or multiple, and family history of tuberous sclerosis.
RESULTS: Eighteen documented cases in which cardiac rhabdomyoma was found during pregnancy were evaluated. Of these cases, seven (39%) had proven tuberous sclerosis and 11 were found to be non-associated tuberous sclerosis tumors. When combining the present data with previous series, cases with diagnosis of tuberous sclerosis had equal mean tumor size to those with normal outcome. Family history of tuberous sclerosis in the presence of cardiac rhabdomyoma almost invariably ended with tuberous sclerosis (86%). All other cases with diagnosis of tuberous sclerosis and no family history had all multiple cardiac tumors.
CONCLUSION: The present data suggest that 39% of in utero suspected cardiac rhabdomyoma would have tuberous sclerosis. Family history and multifocality remain the strongest predictors of tuberous sclerosis, whereas size of the cardiac tumor can not reliably be used to predict tuberous sclerosis in prenatal counseling. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2002        PMID: 12424773     DOI: 10.1002/pd.464

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  8 in total

1.  Prenatal and Postnatal Diagnosis of Rhabdomyomas and Tuberous Sclerosis Complex by Ultrafast and Standard MRI.

Authors:  Ying Zhou; Su-Zhen Dong; Yu-Min Zhong; Ai-Min Sun
Journal:  Indian J Pediatr       Date:  2018-01-09       Impact factor: 1.967

2.  Fetal demise secondary to massive rhabdomyoma in the early second trimester of pregnancy.

Authors:  J Sharma; S Inglis; R Cavalieri; I Udom-Rice
Journal:  Pediatr Cardiol       Date:  2010-12-25       Impact factor: 1.655

Review 3.  Assessment of cortical maturation with prenatal MRI: part II: abnormalities of cortical maturation.

Authors:  Céline Fogliarini; Katia Chaumoitre; Frédérique Chapon; Carla Fernandez; Olivier Lévrier; Dominique Figarella-Branger; Nadine Girard
Journal:  Eur Radiol       Date:  2005-04-21       Impact factor: 5.315

Review 4.  [Indications for fetal magnetic resonance imaging].

Authors:  D Prayer; P C Brugger; E Krampl; L Prayer
Journal:  Radiologe       Date:  2006-02       Impact factor: 0.635

5.  Sonographic diagnosis of fetal cardiac rhabdomyomas and cerebral tubers: a case report of prenatal Tuberous Sclerosis.

Authors:  Enrico Colosi; Carlo Russo; Gabriele Macaluso; Rosalia Musone; Chiara Catalano
Journal:  J Prenat Med       Date:  2013-10

6.  Early onset of tuberous sclerosis with chylous ascites: a case report.

Authors:  Hosein Dalili; Elahe Amini; Parvin Akbari Asbagh; Tahereh Esmaeilnia Shrivany; Nikoo Niknafs; Fatemeh Nayyeri; Mamak Shariat; Saharnaz Talebian; Naser Akbari Asbagh; Vafa Ghorban Sabagh
Journal:  Iran J Public Health       Date:  2015-03       Impact factor: 1.429

7.  Right atrial cardiac rhabdomyoma with premature foramen ovale restriction: A case report.

Authors:  Yi-Dan Li; Yi-Hua He; Zhi-An Li; Ping Wei
Journal:  Oncol Lett       Date:  2014-10-10       Impact factor: 2.967

Review 8.  A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC).

Authors:  Johann Philipp Zöllner; David Neal Franz; Christoph Hertzberg; Rima Nabbout; Felix Rosenow; Matthias Sauter; Susanne Schubert-Bast; Adelheid Wiemer-Kruel; Adam Strzelczyk
Journal:  Orphanet J Rare Dis       Date:  2020-01-21       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.